28th Sep 2020 19:33
Angle PLC - liquid biopsy company - Submits full De Novo US Food & Drug Administration submission for Parsortix PC1 system for clearance to be used for metastatic breast cancer patients. Due to being a De Novo process, the outcome and timing of submission is dependent wholly on FDA's review.
"We believe that FDA regulatory clearance, considered the gold standard for approval of medical diagnostic systems globally, would further competitively differentiate our Parsortix liquid biopsy system and should lead to an acceleration in commercial adoption of the system in both research and clinical settings," says Chief Executive Andrew Newland.
Current stock price: 56.00 pence
Year-to-date change: down 11%
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle